Panuveitis - Market Insights, Epidemiology, and Market Forecast - 2034
Description
Key Highlights
The Panuveitis market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted panuveitis market size from 2020 to 2034 in 7MM. The report also covers current panuveitis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Geography Covered
Panuveitis Overview
Panuveitis, also known as diffuse uveitis, is a rare but serious ophthalmic condition characterized by inflammation involving all layers of the uvea, which includes the iris, ciliary body, and choroid, leading to diffuse intraocular inflammation without a predominant site. This widespread inflammation can also affect adjacent ocular structures such as the retina, vitreous humor, and optic nerve, potentially leading to significant complications, including vision loss. Panuveitis can be triggered by various underlying causes, including infectious agents, autoimmune or autoinflammatory disorders, ocular trauma, intraocular malignancies, or exposure to toxic substances. The common symptoms of panuveitis include blurred vision, eye flashes, floaters, pain in the eye, eye watering, redness, and photophobia (sensitivity to light).
Panuveitis Diagnosis
The diagnosis of panuveitis involves a thorough ocular examination and a detailed medical history to identify the extent and cause of inflammation. The key diagnostic procedures include slit-lamp examination to assess inflammation in the anterior segment of the eye and ophthalmoscopy to evaluate the posterior segment, including the retina and choroid. Advanced imaging techniques such as fluorescein angiography are used to visualize blood flow in the retina and choroid, while optical coherence tomography (OCT) helps assess retinal thickness and detect structural changes. Further, laboratory tests such as blood testing and imaging studies are also crucial to identify any underlying systemic diseases or infections. The accurate diagnosis through these methods is essential for determining the appropriate treatment plan and effectively managing potential complications associated with panuveitis.
Further details related to country-based variations in diagnosis are provided in the report
Panuveitis Treatment
The primary treatment of panuveitis involves the use of corticosteroids to reduce inflammation, protect vision, and alleviate discomfort. Depending on the severity, corticosteroids may be administered as topical eye drops for anterior inflammation, oral steroids for more extensive involvement, or intravitreal injections for localized ocular inflammation. For patients with non-infectious panuveitis or those refractory to steroids, immunosuppressive agents such as methotrexate, azathioprine, cyclosporine, or biologic therapies like infliximab and adalimumab may be utilized. In cases of infectious panuveitis, targeted antimicrobial treatments, including antibiotics, antivirals, antifungals, or antiparasitics, are essential to eliminate the causative pathogens. When medical management alone is insufficient, surgical interventions such as vitrectomy to remove the vitreous humor or cataract surgery to address lens opacities may be required to preserve or restore vision.
Further details related to treatment will be provided in the report…
Panuveitis Epidemiology
The panuveitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total prevalent cases of panuveitis, total diagnosed prevalent cases of panuveitis, age-specific diagnosed prevalent cases of panuveitis, type- specific diagnosed prevalent cases of panuveitis and total treated cases of panuveitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.
The drug chapter segment of panuveitis report encloses a detailed analysis of panuveitis-marketed drugs and emerging pipeline drugs. It also deep dives into panuveitis pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.
Marketed Drugs
HUMIRA (adalimumab): AbbVie
Adalimumab is a biologic agent that works by blocking tumor necrosis factor-alpha (TNFα), an inflammatory protein. It is administered as a subcutaneous injection. It is the only FDA-approved systemic non-corticosteroid therapy for the treatment of non-infectious panuveitis in adults and children aged 2 years and older.
Emerging Drugs
Brepocitinib: Priovant Therapeutics
Brepocitinib, an oral once-daily dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1). By selectively inhibiting both TYK2 and JAK1, brepocitinib is optimized to suppress signaling of a wide range of TYK2- and JAK1-dependent cytokines linked to autoimmunity, including type I and type II interferon, IL-6, IL-12, and IL-23. Currently, the drug is being evaluated in Phase III clinical stage of development for the treatment of non-anterior uveitis including panuveitis.
In September 2024, the company announced the US FDA had granted Fast Track Designation to brepocitinib for non-anterior non-infectious uveitis including panuveitis.
Vamikibart: Roche
Vamikibart is an investigational humanized monoclonal antibody that targets interleukin-6 (IL-6). The drug is currently being evaluated in patients with uveitic macular edema secondary to noninfectious uveitis, including panuveitis. Currently, the drug is in Phase III clinical trial. The Primary completion date of the trial was May 2025.
Drug Class Insights
TYK2/JAK1 inhibitors
TYK2/JAK1 inhibitors are a class of targeted therapies that modulate key immune pathways involved in panuveitis by blocking the activity of tyrosine kinases TYK2 and JAK1. These enzymes play a central role in signaling for multiple pro-inflammatory cytokines that drive ocular inflammation, including interferons and interleukins such as IL-6, IL-12, and IL-23. By inhibiting TYK2 and JAK1, these agents reduce the immune system’s overactive response, helping to control inflammation and prevent tissue damage in panuveitis.
Panuveitis Market Outlook
The current therapeutic approaches for the treatment of panuveitis are primarily focused on alleviating symptoms, reducing inflammation and preventing severe damage to the eyes. The non-specific treatment options for panuveitis include corticosteroids, biologic therapies (such as infliximab, adalimumab), immunosuppressants, disease-modifying antirheumatic drugs (DMARDs), and cycloplegics.
Currently, HUMIRA (adalimumab) remains the only FDA-approved biologic specifically indicated for the treatment of non-infectious panuveitis in both adults and children. However, following the patent expiration of HUMIRA in early 2023, the US market has seen the introduction of approximately ten FDA-approved adalimumab biosimilars, including AMJEVITA, CYLTEZO, HYRIMOZ, HADLIMA, ABRILADA, HULIO, YUSIMRY, IDACIO, YUFLYMA, and SIMLANDI. Notably, SIMLANDI, which gained approval in February 2024, is distinguished as the first high-concentration, citrate-free interchangeable biosimilar to HUMIRA, offering a more comfortable injection experience and greater dosing flexibility.
The arrival of these biosimilars has expanded access to adalimumab therapy, potentially reducing costs and increasing options for patients requiring long-term management of panuveitis. Further, the dynamics of panuveitis market is anticipated to change in the coming years comprising several therapeutic candidates currently under investigation, including Brepocitinib (Priovant Therapeutics), Vamikibart (Roche), among others.
Panuveitis Drug Uptake
This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025–2034. The landscape of panuveitis treatment has experienced a profound transformation with the uptake of novel medicines. These innovative therapies are redefining standards of care.
Further detailed analysis of emerging therapies' drug uptake in the report.
Panuveitis Pipeline Development Activities
The report provides insights into different therapeutic candidates in the marketed and emerging stages. It also analyses key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for panuveitis therapies.
KOL Views
To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Professors, and others.
DelveInsight’s analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Milan, University of Utah, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or panuveitis market trends.
Qualitative Analysis
We perform qualitative and market intelligence analysis using various approaches, such as SWOT and conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyses multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyse the effectiveness of therapy. The analyst analyses multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated. Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.
Market Access and Reimbursement
Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- Panuveitis is a severe form of uveitis characterized by inflammation of all layers of the uveal tract (iris, ciliary body, and choroid), often extending to the retina and vitreous humor. Although less common than anterior uveitis, it is clinically significant due to its severity and high risk of vision loss.
- The prevalence of uveitis is lower in the pediatric population, with approximately 30 cases per 100,000 individuals, compared to 93 cases per 100,000 in adults.
- In the United States, panuveitis is the most prevalent form of nonanterior noninfectious uveitis (NIU) in adults aged 18 ̶ 30 years, accounting for approximately 55% of nonanterior cases, with a prevalence of 5 cases per 100,000 individuals.
- Current standard treatment options include corticosteroids, immunosuppressive agents, biologics (such as infliximab, adalimumab), disease-modifying antirheumatic drugs (DMARDs), and cycloplegics.
- Currently, there is only one FDA-approved drug, HUMIRA (adalimumab) for the treatment of panuveitis with around ten FDA-approved biosimilars. The biosimilars include AMJEVITA, CYLTEZO, HYRIMOZ, HADLIMA, ABRILADA, HULIO, YUSIMRY, IDACIO, YUFLYMA, and SIMLANDI.
- The major key players in the development of novel therapies for panuveitis include Priovant Therapeutics (Brepocitinib), Roche (Vamikibart), and others.
The Panuveitis market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted panuveitis market size from 2020 to 2034 in 7MM. The report also covers current panuveitis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Panuveitis Overview
Panuveitis, also known as diffuse uveitis, is a rare but serious ophthalmic condition characterized by inflammation involving all layers of the uvea, which includes the iris, ciliary body, and choroid, leading to diffuse intraocular inflammation without a predominant site. This widespread inflammation can also affect adjacent ocular structures such as the retina, vitreous humor, and optic nerve, potentially leading to significant complications, including vision loss. Panuveitis can be triggered by various underlying causes, including infectious agents, autoimmune or autoinflammatory disorders, ocular trauma, intraocular malignancies, or exposure to toxic substances. The common symptoms of panuveitis include blurred vision, eye flashes, floaters, pain in the eye, eye watering, redness, and photophobia (sensitivity to light).
Panuveitis Diagnosis
The diagnosis of panuveitis involves a thorough ocular examination and a detailed medical history to identify the extent and cause of inflammation. The key diagnostic procedures include slit-lamp examination to assess inflammation in the anterior segment of the eye and ophthalmoscopy to evaluate the posterior segment, including the retina and choroid. Advanced imaging techniques such as fluorescein angiography are used to visualize blood flow in the retina and choroid, while optical coherence tomography (OCT) helps assess retinal thickness and detect structural changes. Further, laboratory tests such as blood testing and imaging studies are also crucial to identify any underlying systemic diseases or infections. The accurate diagnosis through these methods is essential for determining the appropriate treatment plan and effectively managing potential complications associated with panuveitis.
Further details related to country-based variations in diagnosis are provided in the report
Panuveitis Treatment
The primary treatment of panuveitis involves the use of corticosteroids to reduce inflammation, protect vision, and alleviate discomfort. Depending on the severity, corticosteroids may be administered as topical eye drops for anterior inflammation, oral steroids for more extensive involvement, or intravitreal injections for localized ocular inflammation. For patients with non-infectious panuveitis or those refractory to steroids, immunosuppressive agents such as methotrexate, azathioprine, cyclosporine, or biologic therapies like infliximab and adalimumab may be utilized. In cases of infectious panuveitis, targeted antimicrobial treatments, including antibiotics, antivirals, antifungals, or antiparasitics, are essential to eliminate the causative pathogens. When medical management alone is insufficient, surgical interventions such as vitrectomy to remove the vitreous humor or cataract surgery to address lens opacities may be required to preserve or restore vision.
Further details related to treatment will be provided in the report…
Panuveitis Epidemiology
The panuveitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total prevalent cases of panuveitis, total diagnosed prevalent cases of panuveitis, age-specific diagnosed prevalent cases of panuveitis, type- specific diagnosed prevalent cases of panuveitis and total treated cases of panuveitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.
- In the United States, panuveitis is generally considered one of the least common types of pediatric uveitis, accounting for approximately 14 ̶ 21% of cases.
- In Japan, panuveitis represents the most prevalent form of uveitis, accounting for approximately 45.56% cases.
The drug chapter segment of panuveitis report encloses a detailed analysis of panuveitis-marketed drugs and emerging pipeline drugs. It also deep dives into panuveitis pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.
Marketed Drugs
HUMIRA (adalimumab): AbbVie
Adalimumab is a biologic agent that works by blocking tumor necrosis factor-alpha (TNFα), an inflammatory protein. It is administered as a subcutaneous injection. It is the only FDA-approved systemic non-corticosteroid therapy for the treatment of non-infectious panuveitis in adults and children aged 2 years and older.
Emerging Drugs
Brepocitinib: Priovant Therapeutics
Brepocitinib, an oral once-daily dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1). By selectively inhibiting both TYK2 and JAK1, brepocitinib is optimized to suppress signaling of a wide range of TYK2- and JAK1-dependent cytokines linked to autoimmunity, including type I and type II interferon, IL-6, IL-12, and IL-23. Currently, the drug is being evaluated in Phase III clinical stage of development for the treatment of non-anterior uveitis including panuveitis.
In September 2024, the company announced the US FDA had granted Fast Track Designation to brepocitinib for non-anterior non-infectious uveitis including panuveitis.
Vamikibart: Roche
Vamikibart is an investigational humanized monoclonal antibody that targets interleukin-6 (IL-6). The drug is currently being evaluated in patients with uveitic macular edema secondary to noninfectious uveitis, including panuveitis. Currently, the drug is in Phase III clinical trial. The Primary completion date of the trial was May 2025.
Drug Class Insights
TYK2/JAK1 inhibitors
TYK2/JAK1 inhibitors are a class of targeted therapies that modulate key immune pathways involved in panuveitis by blocking the activity of tyrosine kinases TYK2 and JAK1. These enzymes play a central role in signaling for multiple pro-inflammatory cytokines that drive ocular inflammation, including interferons and interleukins such as IL-6, IL-12, and IL-23. By inhibiting TYK2 and JAK1, these agents reduce the immune system’s overactive response, helping to control inflammation and prevent tissue damage in panuveitis.
Panuveitis Market Outlook
The current therapeutic approaches for the treatment of panuveitis are primarily focused on alleviating symptoms, reducing inflammation and preventing severe damage to the eyes. The non-specific treatment options for panuveitis include corticosteroids, biologic therapies (such as infliximab, adalimumab), immunosuppressants, disease-modifying antirheumatic drugs (DMARDs), and cycloplegics.
Currently, HUMIRA (adalimumab) remains the only FDA-approved biologic specifically indicated for the treatment of non-infectious panuveitis in both adults and children. However, following the patent expiration of HUMIRA in early 2023, the US market has seen the introduction of approximately ten FDA-approved adalimumab biosimilars, including AMJEVITA, CYLTEZO, HYRIMOZ, HADLIMA, ABRILADA, HULIO, YUSIMRY, IDACIO, YUFLYMA, and SIMLANDI. Notably, SIMLANDI, which gained approval in February 2024, is distinguished as the first high-concentration, citrate-free interchangeable biosimilar to HUMIRA, offering a more comfortable injection experience and greater dosing flexibility.
The arrival of these biosimilars has expanded access to adalimumab therapy, potentially reducing costs and increasing options for patients requiring long-term management of panuveitis. Further, the dynamics of panuveitis market is anticipated to change in the coming years comprising several therapeutic candidates currently under investigation, including Brepocitinib (Priovant Therapeutics), Vamikibart (Roche), among others.
Panuveitis Drug Uptake
This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025–2034. The landscape of panuveitis treatment has experienced a profound transformation with the uptake of novel medicines. These innovative therapies are redefining standards of care.
Further detailed analysis of emerging therapies' drug uptake in the report.
Panuveitis Pipeline Development Activities
The report provides insights into different therapeutic candidates in the marketed and emerging stages. It also analyses key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for panuveitis therapies.
KOL Views
To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Professors, and others.
DelveInsight’s analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Milan, University of Utah, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or panuveitis market trends.
Qualitative Analysis
We perform qualitative and market intelligence analysis using various approaches, such as SWOT and conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyses multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyse the effectiveness of therapy. The analyst analyses multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated. Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.
Market Access and Reimbursement
Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report
- The report covers a segment of key events, an executive summary, a descriptive overview of panuveitis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and treatment guidelines.
- Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
- A detailed review of the panuveitis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends, through SWOT and conjoint analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM panuveitis market.
- Patient Population
- Therapeutic Approaches
- Panuveitis Pipeline Analysis
- Panuveitis Market Size and Trends
- Existing and Future Market Opportunity
- Ten-Year Forecast
- 7MM Coverage
- Panuveitis Epidemiology Segmentation
- Key Cross Competition
- Conjoint analysis
- Drugs Uptake and Key Market Forecast Assumptions
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint)
- What was the panuveitis total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors for this growth?
- At what CAGR, panuveitis market is expected to grow at the 7MM level during the study period (2020–2034)?
- How is Japan's panuveitis competitive landscape evolving?
- How will upcoming emerging therapies are going to impact HUMIRA’s market share?
- What are the disease risks, burdens, and unmet needs of panuveitis?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to panuveitis?
- What is the historical and forecasted panuveitis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
- What factors are affecting the increase in the diagnosis of symptomatic cases?
- What are the current options for the treatment of panuveitis? What are the current treatment guidelines for the treatment of panuveitis in the US and Europe?
- How many companies are developing therapies for the treatment of panuveitis?
- Which key designations have been granted for the emerging therapies for panuveitis?
- What is the cost burden of approved therapies on the patient?
- Patient acceptability in terms of preferred treatment options as per real-world scenarios?
- What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
- The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics and driving factor for panuveitis market.
- Insights on patient share/disease burden, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Identifying upcoming players in the market will help devise strategies to help get ahead of competitors.
- Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
- To understand KOLs’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
200 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Epidemiology and Market Forecast Methodology
- 4. Panuveitis: Market Overview at a Glance
- 4.1. Total Market Share (%) Distribution of Panuveitis by Therapies in 2024
- 4.2. Total Market Share (%) Distribution of Panuveitis by Therapies in 2034
- 5. Executive Summary of Panuveitis
- 6. Key Events of Panuveitis
- 7. Panuveitis: Disease Background and Overview
- 7.1. Introduction
- 7.2. Signs and Symptoms
- 7.3. Causes
- 7.4. Diagnosis
- 7.4.1. Diagnosis Guidelines
- 7.4.2. Diagnosis Algorithm
- 8. Treatment
- 8.1. Treatment Guidelines
- 8.2. Treatment Algorithm
- 9. Epidemiology and Patient Population of Panuveitis
- 9.1. Key Findings
- 9.2. Assumptions and Rationale: The 7MM
- 9.3. Total Diagnosed Prevalent Cases of Panuveitis in the 7MM
- 9.4. The United States
- 9.4.1. Total Prevalent Cases of Panuveitis in the United States
- 9.4.2. Total Diagnosed Prevalent Cases of Panuveitis in the United States
- 9.4.3. Age-specific Diagnosed Prevalent Cases of Panuveitis in the United States
- 9.4.4. Type-specific Diagnosed Prevalent Cases of Panuveitis in the United States
- 9.4.5. Total Treated Cases of Panuveitis in the United States
- 9.5. EU4 and the UK
- 9.5.1. Total Prevalent Cases of Panuveitis in EU4 and the UK
- 9.5.2. Diagnosed Prevalent Cases of Panuveitis in EU4 and the UK
- 9.5.3. Age-specific Diagnosed Prevalent Cases of Panuveitis in EU4 and the UK
- 9.5.4. Type-specific Diagnosed Prevalent Cases of Panuveitis in EU4 and the UK
- 9.5.5. Total Treated Cases of Panuveitis in EU4 and the UK
- 9.6. Japan
- 9.6.1. Total Prevalent Cases of Panuveitis in Japan
- 9.6.2. Diagnosed Prevalent Cases of Panuveitis in Japan
- 9.6.3. Age-specific Diagnosed Prevalent Cases of Panuveitis in Japan
- 9.6.4. Type-specific Diagnosed Prevalent Cases of Panuveitis in Japan
- 9.6.5. Total Treated Cases of Panuveitis in Japan
- 10. Patient Journey
- 11. Marketed Therapies of Panuveitis
- 11.1. Key Competitors
- 11.2. HUMIRA (adalimumab): AbbVie
- 11.2.1. Product Description
- 11.2.2. Regulatory Milestones
- 11.2.3. Other Developmental Activities
- 11.2.4. Clinical Development
- 11.2.4.1. Clinical Trials Information
- 11.2.5. Safety and efficacy
- 11.2.6. Analyst Views
- List to be continued in the report…
- 12. Emerging Drugs
- 12.1. Key Competitors
- 12.2. Brepocitinib: Priovant Therapeutics
- 12.2.1. Product Description
- 12.2.2. Other Developmental Activities
- 12.2.3. Clinical Development
- 12.2.3.1. Clinical Trials Information
- 12.2.4. Safety and Efficacy
- 12.2.5. Analyst Views
- List to be continued in the report…
- 13. Panuveitis: Seven Major Market Analysis
- 13.1. Key Findings
- 13.2. Key Market Forecast Assumptions
- 13.2.1. Cost Assumptions and Rebate
- 13.2.2. Pricing Trends
- 13.2.3. Analogue Assessment
- 13.2.4. Launch Year and Therapy Uptake
- 13.3. Market Outlook
- 13.4. Conjoint Analysis
- 13.5. Total Market Size of Panuveitis in the 7MM
- 13.6. Total Market Size of Panuveitis by Therapies in the 7MM
- 13.7. The United States
- 13.7.1. Total Market Size of Panuveitis
- 13.7.2. The Market Size of Panuveitis by Therapies
- 13.8. EU4 and the UK
- 13.8.1. Total Market Size of Panuveitis
- 13.8.2. The Market Size of Panuveitis by Therapies
- 13.9. Japan
- 13.9.1. Total Market Size of Panuveitis
- 13.9.2. The Market Size of Panuveitis by Therapies
- 14. Unmet Needs
- 15. SWOT Analysis
- 16. KOL Views
- 17. Market Access and Reimbursement
- 18. Appendix
- 18.1. Bibliography
- 18.2. Report Methodology
- 19. DelveInsight Capabilities
- 20. Disclaimer
- 21. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
